StreetInsider.com News Articles

Davion Healthcare agrees $13.5M deal for US home health firm

Thu, 29 Oct 2026 07:30:22 -0400

Davion Healthcare Plc (NASDAQ: DAVI), a Dublin-based developer of non-invasive health monitoring technologies, has agreed to acquire Healthcare Stat Homecare Inc. (HSH), a Philadelphia-based home healthcare provider, for $13.5 million, according to a company press release.

The consideration consists of $8 million in cash and $5.5 million in Davion shares, issued at an agreed value of $13 per share. The deal, signed Oct. 27, 2026, is expected to close on or before Dec. 31, 2026, subject to the terms of the acquisition agreement.

HSH reported gross receipts of approximately $11.6 million and ordinary business income of approximately $1.9 million for the year

Davion Healthcare PLC Agrees $13.5 Million Acquisition of Profitable US Home Healthcare Business

Thu, 29 Oct 2026 07:30:00 -0400

First in a planned programme of acquisitions to expand Davion’s revenues, earnings and healthcare operations

DUBLIN, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (NASDAQ: DAVI) (“Davion” or the “Group”), a developer of non-invasive health monitoring technologies, announces that it has entered into an agreement dated 27 October 2026 to acquire Healthcare Stat Homecare Inc. (“HSH”), a Pennsylvania-incorporated provider of home healthcare services based in Philadelphia.

The total consideration is $13.5 million, comprising $8 million in cash and $5.5 million in Davion shares issued at an agreed value of $13 per share. Completion is expected on or

Davion Healthcare PLC Agrees $13.5 Million Acquisition of Profitable US Home Healthcare Business

Thu, 29 Oct 2026 07:30:00 -0400

First in a planned programme of acquisitions to expand Davion’s revenues, earnings and healthcare operations

The total consideration is $13.5 million, comprising $8 million in cash and $5.5 million in Davion shares issued at an agreed value of $13 per share. Completion is expected on or

Davion Healthcare acquires Humaskan medical IP for $25 million

Mon, 26 Oct 2026 07:30:17 -0400

Davion Healthcare Plc (Nasdaq: DAVI) has completed the acquisition of intellectual property relating to two medical technologies from the four shareholders of Humaskan Ltd for a total consideration of $25 million, according to a company statement.

The consideration comprises $2.5 million in cash and 1,730,770 new ordinary shares in Davion, issued at a fixed contractual value of $13.00 per share, representing approximately $22.5 million. The number of shares is fixed and will not vary with movements in Davion's share price.

The acquired technologies are WoundSkan, a smart wound-monitoring dressing, and the Spektra Lateral Flow Test, a rapid multi-marker screening platform. WoundSkan uses

Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP

Mon, 26 Oct 2026 07:30:00 -0400

Acquisition adds battery-free smart wound dressing and two-minute multi-marker screening test to Davion’s growing healthcare portfolio

DUBLIN, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Davion Healthcare Plc (Nasdaq: DAVI) ("Davion" or the "Company"), a next-generation digital healthcare company developing proprietary health monitoring technologies, today announces that it has completed the acquisition of the intellectual property relating to two medical technologies: WoundSkan, a smart wound-monitoring dressing, and the Spektra Lateral Flow Test, a rapid multi-marker screening platform.

The intellectual property was acquired from the four shareholders of Humaskan Ltd for a total consideration of US$25 million, comprising US$2.5

Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP

Mon, 26 Oct 2026 07:30:00 -0400

Acquisition adds battery-free smart wound dressing and two-minute multi-marker screening test to Davion’s growing healthcare portfolio

The intellectual property was acquired from the four shareholders of Humaskan Ltd for a total consideration of US$25 million, comprising US$2.5

Davion Healthcare to begin Nasdaq trading under ticker DAVI

Tue, 20 Oct 2026 06:24:40 -0400

Davion Healthcare Plc, a Dublin-based digital health company, said its ordinary shares are expected to begin trading on the Nasdaq Global Market on Oct. 22, 2026, under the ticker symbol "DAVI" (Nasdaq: DAVI).

The company appointed Glenn Williams as Chief Executive Officer and Jeremy North as Chief Operating Officer, with both roles taking effect upon commencement of trading. Current CEO Jack Kaye will become Chairman, while Sir Eric Peacock will step down as Chairman and remain on the board as a Non-Executive Director.

Williams brings more than 35 years of experience in healthcare, finance and operations, and has been involved in more

DAVION HEALTHCARE PLC CONFIRMS EXPECTED NASDAQ TRADING DATE AND ANNOUNCES NEW EXECUTIVE LEADERSHIP AND OPERATING STRUCTURE

Tue, 20 Oct 2026 06:22:00 -0400

Ordinary shares expected to commence trading on Nasdaq Global Market on Thursday 22 October 2026 under ticker "DAVI"

Glenn Williams appointed Chief Executive Officer and Jeremy North Chief Operating Officer, effective on commencement of trading

New Operational Directorate established to lead commercialisation, operations, acquisitions and execution of the Group's growth

DAVION HEALTHCARE PLC CONFIRMS EXPECTED NASDAQ TRADING DATE AND ANNOUNCES NEW EXECUTIVE LEADERSHIP AND OPERATING STRUCTURE

Tue, 20 Oct 2026 06:22:00 -0400

Ordinary shares expected to commence trading on Nasdaq Global Market on Thursday 22 October 2026 under ticker "DAVI"

Glenn Williams appointed Chief Executive Officer and Jeremy North Chief Operating Officer, effective on commencement of trading

New Operational Directorate established to lead commercialisation, operations, acquisitions and execution of the Group's growth

DAVION HEALTHCARE PLC CONFIRMS EXPECTED NASDAQ TRADING DATE AND ANNOUNCES NEW EXECUTIVE LEADERSHIP AND OPERATING STRUCTURE

Tue, 20 Oct 2026 06:22:00 -0400

Ordinary shares expected to commence trading on Nasdaq Global Market on Thursday 22 October 2026 under ticker "DAVI"

Glenn Williams appointed Chief Executive Officer and Jeremy North Chief Operating Officer, effective on commencement of trading

New Operational Directorate established to lead commercialisation, operations, acquisitions and execution of the Group's growth

DAVION HEALTHCARE PLC CONFIRMS EXPECTED NASDAQ TRADING DATE AND ANNOUNCES NEW EXECUTIVE LEADERSHIP AND OPERATING STRUCTURE

Tue, 20 Oct 2026 06:22:00 -0400

Ordinary shares expected to commence trading on Nasdaq Global Market on Thursday 22 October 2026 under ticker "DAVI"

Glenn Williams appointed Chief Executive Officer and Jeremy North Chief Operating Officer, effective on commencement of trading

New Operational Directorate established to lead commercialisation, operations, acquisitions and execution of the Group's growth

Davion Healthcare appoints new CFO and non-executive director

Tue, 02 Dec 2025 11:23:42 -0400

Davion Healthcare Plc announced the appointment of Andreas Ttofi as Chief Financial Officer and Jan Dulman as Independent Non-Executive Director and Chair of the Audit Committee, both effective immediately.

Ttofi is an ACCA Member with over a decade of experience in audit, financial reporting, taxation, and operational finance. Since 2012, he has advised corporate and private clients across multiple sectors, according to the company statement.

Dulman is a Certified Public Accountant with experience as a CFO, audit professional, and senior accounting partner. He previously served as Controller and CFO of a publicly listed mining exploration company and founded a CPA partnership that

Davion Healthcare appoints new CFO and non-executive director

Tue, 02 Dec 2025 11:23:42 -0400

Davion Healthcare Plc announced the appointment of Andreas Ttofi as Chief Financial Officer and Jan Dulman as Independent Non-Executive Director and Chair of the Audit Committee, both effective immediately.

Ttofi is an ACCA Member with over a decade of experience in audit, financial reporting, taxation, and operational finance. Since 2012, he has advised corporate and private clients across multiple sectors, according to the company statement.

Dulman is a Certified Public Accountant with experience as a CFO, audit professional, and senior accounting partner. He previously served as Controller and CFO of a publicly listed mining exploration company and founded a CPA partnership that

Davion Healthcare Plc Announces Appointment of New Chief Financial Officer and Independent Non-Executive Director

Tue, 02 Dec 2025 11:23:00 -0400

New York, Dec. 2, 2025 /PRNewswire/ -- Davion Healthcare Plc ("Davion" or the "Company"), the medical technology company advancing non-invasive home tests for various medical anomalies including cancer, today announced the appointment of Mr. Andreas Ttofi as Chief Financial Officer and Mr. Jan Dulman, CPA, as Independent Non-Executive Director and Chair of the Audit Committee, both effective immediately.

Andreas Ttofi – Chief Financial Officer
Mr. Ttofi is a fully qualified ACCA Member and accomplished accountant with over a decade of professional experience in audit, financial reporting, taxation, and operational finance. Since 2012, he has advised a

Davion Healthcare Plc Announces Appointment of New Chief Financial Officer and Independent Non-Executive Director

Tue, 02 Dec 2025 11:23:00 -0400

New York, Dec. 2, 2025 /PRNewswire/ -- Davion Healthcare Plc ("Davion" or the "Company"), the medical technology company advancing non-invasive home tests for various medical anomalies including cancer, today announced the appointment of Mr. Andreas Ttofi as Chief Financial Officer and Mr. Jan Dulman, CPA, as Independent Non-Executive Director and Chair of the Audit Committee, both effective immediately.

Andreas Ttofi – Chief Financial Officer
Mr. Ttofi is a fully qualified ACCA Member and accomplished accountant with over a decade of professional experience in audit, financial reporting, taxation, and operational finance. Since 2012, he has advised a

Davion Healthcare Plc Announces Appointment of New Chief Financial Officer and Independent Non-Executive Director

Tue, 02 Dec 2025 11:23:00 -0400

New York, Dec. 2, 2025 /PRNewswire/ -- Davion Healthcare Plc ("Davion" or the "Company"), the medical technology company advancing non-invasive home tests for various medical anomalies including cancer, today announced the appointment of Mr. Andreas Ttofi as Chief Financial Officer and Mr. Jan Dulman, CPA, as Independent Non-Executive Director and Chair of the Audit Committee, both effective immediately.

Andreas Ttofi – Chief Financial Officer
Mr. Ttofi is a fully qualified ACCA Member and accomplished accountant with over a decade of professional experience in audit, financial reporting, taxation, and operational finance. Since 2012, he has advised a

Davion Healthcare Plc Announces Appointment of New Chief Financial Officer and Independent Non-Executive Director

Tue, 02 Dec 2025 11:23:00 -0400

New York, Dec. 2, 2025 /PRNewswire/ -- Davion Healthcare Plc ("Davion" or the "Company"), the medical technology company advancing non-invasive home tests for various medical anomalies including cancer, today announced the appointment of Mr. Andreas Ttofi as Chief Financial Officer and Mr. Jan Dulman, CPA, as Independent Non-Executive Director and Chair of the Audit Committee, both effective immediately.

Andreas Ttofi – Chief Financial Officer
Mr. Ttofi is a fully qualified ACCA Member and accomplished accountant with over a decade of professional experience in audit, financial reporting, taxation, and operational finance. Since 2012, he has advised a

Davion Healthcare's F-1 registration statement becomes effective

Fri, 28 Nov 2025 10:00:34 -0400

Davion Healthcare Plc (NASDAQ: DAVI) announced that its Registration Statement on Form F-1, filed with the U.S. Securities and Exchange Commission on November 7, 2025, has become automatically effective under Section 8(a) of the Securities Act of 1933.
The medical technology company also filed a Form 8-A to register its ordinary shares under Section 12(b) of the Securities Exchange Act of 1934 in connection with the F-1's effectiveness.
Davion stated it is completing remaining administrative steps with The Nasdaq Stock Market regarding admission of its ordinary shares for trading. The company said it will make a further announcement once it receives confirmation

Davion Healthcare's F-1 registration statement becomes effective

Fri, 28 Nov 2025 10:00:34 -0400

Davion Healthcare Plc (NASDAQ: DAVI) announced that its Registration Statement on Form F-1, filed with the U.S. Securities and Exchange Commission on November 7, 2025, has become automatically effective under Section 8(a) of the Securities Act of 1933.
The medical technology company also filed a Form 8-A to register its ordinary shares under Section 12(b) of the Securities Exchange Act of 1934 in connection with the F-1's effectiveness.
Davion stated it is completing remaining administrative steps with The Nasdaq Stock Market regarding admission of its ordinary shares for trading. The company said it will make a further announcement once it receives confirmation

DAVION HEALTHCARE PLC FORM F-1 BECOMES AUTOMATICALLY EFFECTIVE UNDER SECTION 8(a)

Fri, 28 Nov 2025 10:00:00 -0400

NEW YORK, Nov. 28, 2025 /PRNewswire/ -- Davion Healthcare Plc ("Davion" or the "Company"), the medical technology company developing non-invasive home tests for early-stage identification of various medical anomalies including cancer, today announced that its Registration Statement on Form F-1, filed with the U.S. Securities and Exchange Commission on November 7, 2025, has become automatically effective in accordance with Section 8(a) of the Securities Act of 1933.

In connection with the effectiveness of the Form F-1, Davion has also filed a Form 8-A to register its ordinary shares under Section 12(b) of the Securities Exchange

DAVION HEALTHCARE PLC FORM F-1 BECOMES AUTOMATICALLY EFFECTIVE UNDER SECTION 8(a)

Fri, 28 Nov 2025 10:00:00 -0400

NEW YORK, Nov. 28, 2025 /PRNewswire/ -- Davion Healthcare Plc ("Davion" or the "Company"), the medical technology company developing non-invasive home tests for early-stage identification of various medical anomalies including cancer, today announced that its Registration Statement on Form F-1, filed with the U.S. Securities and Exchange Commission on November 7, 2025, has become automatically effective in accordance with Section 8(a) of the Securities Act of 1933.

In connection with the effectiveness of the Form F-1, Davion has also filed a Form 8-A to register its ordinary shares under Section 12(b) of the Securities Exchange

Davion Healthcare files for direct NASDAQ listing under ticker DAVI

Mon, 04 Aug 2025 12:19:04 -0400

Davion Healthcare Plc filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed direct listing of its ordinary shares on the NASDAQ Global Market under the ticker symbol "DAVI."
The Irish-registered company, which specializes in non-invasive medical technologies, is not conducting an initial public offering and will not raise new capital through this listing. The registration statement covers only existing ordinary shares held by current shareholders.
The registration statement has been filed with the SEC but has not yet become effective. The company's ordinary shares cannot be sold until the registration statement becomes effective.
The information

Davion Healthcare files for direct NASDAQ listing under ticker DAVI

Mon, 04 Aug 2025 12:19:04 -0400

Davion Healthcare Plc filed a registration statement on Form F-1 with the U.S. Securities and Exchange Commission for a proposed direct listing of its ordinary shares on the NASDAQ Global Market under the ticker symbol "DAVI."
The Irish-registered company, which specializes in non-invasive medical technologies, is not conducting an initial public offering and will not raise new capital through this listing. The registration statement covers only existing ordinary shares held by current shareholders.
The registration statement has been filed with the SEC but has not yet become effective. The company's ordinary shares cannot be sold until the registration statement becomes effective.
The information